Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
Department of Clinical Research, University Hospital Basel, Basel, Switzerland.
Curr Top Behav Neurosci. 2022;56:3-21. doi: 10.1007/7854_2021_270.
Classic psychedelics, including psilocybin, lysergic acid diethylamide (LSD), dimethyltryptamine, and mescaline, and entactogens/empathogens, especially 3,4-methylenedioxymethamphetamine, have received renewed attention in psychiatric research and may be developed into medications for such indications as anxiety, depression, cluster headache, and posttraumatic stress disorder, among others. However, identifying proper doses is crucial. Controlled study data on dosing using well-characterized pharmaceutical formulations of the substances are scarce. The dose equivalence of different substances, dose-response effects, and subjective effects of different doses are of great interest and practically important for their clinical use in psychotherapy. Furthermore, the so-called microdosing of psychedelics has recently gained popularity, and the first placebo-controlled studies of LSD have been published. This chapter discusses different aspects of psychedelic dosing, including pharmaceutical aspects, definitions and characteristics of different doses, including microdoses, aspects of personalized dosing, and non-pharmacological factors, that can influence the response to psychedelics.
经典致幻剂,包括裸盖菇素、麦角酸二乙基酰胺(LSD)、二甲色胺和三甲氧苯乙胺,以及致幻剂/同感增强剂,特别是 3,4-亚甲二氧基甲基苯丙胺,在精神科研究中重新受到关注,可能被开发为治疗焦虑、抑郁、丛集性头痛和创伤后应激障碍等适应症的药物。然而,确定适当的剂量是至关重要的。关于使用这些物质的经过良好特征描述的药物制剂进行剂量的对照研究数据稀缺。不同物质的剂量等效性、剂量反应效应以及不同剂量的主观效应对于它们在心理治疗中的临床应用具有重要的研究意义和实际价值。此外,最近所谓的微量使用致幻剂已经变得流行起来,并且已经发表了 LSD 的首个安慰剂对照研究。本章讨论了致幻剂剂量的不同方面,包括药物方面、不同剂量(包括微剂量)的定义和特征、个性化剂量方面以及可能影响致幻剂反应的非药物因素。